Biotech

TUSTIN, CA: Encouraging Overall Survival Data Show Consistent Trend With Earlier Tumor Response Rate and PFS Data; Data Further Support Ongoing Randomized Phase II Trial Evaluating Bavituximab With Docetaxel for ...

Afexa's Board Unanimously Confirms Previous Recommendation That Shareholders Reject Paladin's Unsolicited Offer

EDMONTON, ALBERTA: ...

Radiopharmaceutical Market Reached $3.2 Billion in 2010

ROCKVILLE, MD: ...

7th Annual Swedish-American Life Science Summit (SALSS) Draws Global Industry Attention to Stockholm From August 24th Through 26th

STOCKHOLM, SWEDEN: Fred Hassan, Chairman of Bausch + Lomb and Former CEO of Pharmacia, Returns to Sweden to Deliver a Keynote Address on the Importance of Innovation in Ophthalmology ...

All members:	10 563
Register today:	0
Register yesterday:	2
Members online:	0
Guests online:	72

Biotech

Category / Pharmaceuticals & Biotech / Biotech

Med BioGene Reports Financial Results for Q2 2011

Ladenburg Thalmann Initiates Equity Research Analyst Coverage on Aeolus

40 Year Industry Veteran Bill Gallagher of Jag Capital Joins Bio-Solutions Corp.

Paladin's Premium Offer Remains the Best Choice for Afexa Shareholders

Gentel Announces Agreement With Oregon Health & Science University

Afexa Announces Completion of Interim Analysis on COLD-FX Pediatric Multi-Centre Clinical Trial: Encouraging Trend Observed

Lorus Therapeutics Reports Results for Fiscal Year 2011

Horizon Pharma to Present at the 2011 Stifel Nicolaus Healthcare Conference

Bradmer Announces Second Quarter 2011 Operational and Financial Results

Stem Cell Therapeutics Corp. Announces Q2 2011 Financial Results, Election of Board of Directors and Management Appointment

Bionor Pharma ASA Announces Exploratory Study of Its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination With Leading Cancer Drug

Theravance to Present at Investor Conferences in September 2011

Peregrine Reports Promising 20.7 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial

Afexa's Board Unanimously Confirms Previous Recommendation That Shareholders Reject Paladin's Unsolicited Offer

Radiopharmaceutical Market Reached $3.2 Billion in 2010

7th Annual Swedish-American Life Science Summit (SALSS) Draws Global Industry Attention to Stockholm From August 24th Through 26th

No FDA Advisory Committee Meeting Planned in Connection With New Drug Application for CORLUX for Cushing's Syndrome

Gary C. Robb Joins Corcept as Chief Financial Officer

RepliCel Names Tom Kordyback Chief Financial Officer

Prana Receives Michael J. Fox Foundation Grant to Develop PBT434 for Parkinson's Disease

Service Menu

New here

Who is online